A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 8, 2005, Pages 4474-4482

  Storer, Thomas W ^a,b,h   Woodhouse, Linda J ^a   Sattler, Fred ^c   Singh, Atam B ^a   Schroeder, E Todd ^c   Beck, Keith ^d   Padero, MaClara ^a   Mac, Phong ^a   Yarasheski, Kevin E ^e   Geurts, Paul ^f   Willemsen, Arnold ^g   Harms, Marloes K ^f   Bhasin, Shalender ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b El Camino College   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Medical Services Department   (Netherlands)

^g NV Organon   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN GROWTH HORMONE; NANDROLONE DECANOATE; PLACEBO;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; BODY FAT; CACHEXIA; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; EXTRACELLULAR FLUID; FAT BODY; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; PHYSICAL ACTIVITY; PHYSICAL STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL FUNCTION; SUBCUTANEOUS FAT; TOTAL BODY WATER; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ANABOLIC AGENTS; APPETITE; BLOOD GLUCOSE; BODY COMPOSITION; GONADAL STEROID HORMONES; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NANDROLONE; PHYSICAL ENDURANCE; PLACEBOS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEXUALITY; WEIGHT LOSS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 23844444112     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0275     Document Type: Article

References (40)

1. Sherer R 1998 Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting. Semin Oncol 25:92-97
2. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG, Knox TA 1998 The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12:1645-1651
3. Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S 1992 Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 116:320-328
4. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL 2000 Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31:803-805
5. Mulligan K, Tai VW, Schambelan M 1997 Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 15:43-48
6. Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM 1989 Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 84:1288-1293
7. Kotler DP, Tierney AR, Wang J, Pierson Jr RN 1989 Magnitude of bodycell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50:444-447
8. Hellerstein MK, Kahn J, Mudie H, Viteri FM 1990 Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 17:17-33
9. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, Bartsch GE 1998 Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18:80-85
10. Guenter P, Muurahainen N, Simons G, Kosok A, Cohan GR, Rudenstein R, Turner JL 1993 Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 6:1130-1138
11. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL 2000 Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr 24:137-146
12. Beal JE, Oldson R, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV 1995 Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97
13. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA 1994 Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 121:393-399
14. Mulligan K, Grunfeld C, Hellerstein MK, Schambelan M 1993 Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77:956-962
15. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozette SA, Breitmeyer JB 1996 Recombinant human growth hormone in patients with HIV-associated wasting. A randomized placebo-controlled trial. Serostim Study Group. Ann Intern Med 125:873-882
16. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, Nightingale S, Gesundheit N, Watson D, Schade D 1996 Recombinant human growth hormone, insulin-like growth factor-1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:865-872
17. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G 2000 Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283:763-770
18. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, and Beall G 1998 Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155-3162
19. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A 1998 Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:18-26
20. Gold J, High H, Li Y 1996 Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV-infection. AIDS 10:745-752
21. Phanuphak P, Castelo A, Gold J 1998 Treatment of HIV wasting with the anabolic steroid, nandrolone decanoate: a double-blind placebo-controlled trial in Thailand and Brazil. AIDS 12(Suppl):S77
22. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136-143
23. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S 2004 Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 89:718-726
24. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S 2003 Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88:1478-1485
25. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-E1181
26. Cooper CB, Storer TW 2001 Exercise testing and interpretation: a practical approach. Cambridge, UK: Cambridge University Press; 278
27. Buchfuhrer MJ, Hansen JE, Robinson TE, Sue DY, Wasserman K, Whipp BJ 1983 Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol 55:1558-1564
28. Sinha-Hikim I, Arver S, Beall G, Shen R, Guerrero M, Sattler F, Shikuma C, Nelson JC, Landgren BM, Mazer NA, Bhasin S 1998 The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 83:1312-1318
29. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, Azen S 1999 Effect of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with the human immunodeficiency virus. J Clin Endocrinol Metab 84:1268-1276
30. Strawford A, Barbieri T, Neese R, Van Loan M, Christiansen M, Hoh R, Sathyan G, Skowronski R, King J, Hellerstein M 1999 Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Def Syndr Hum Retrovirol 20:137-146
31. Dobs A, Cofrancesco J, Nolten WE, Danoff A, Anderson R, Hamilton CD, Feinberg J, Seekins D, Yangco B, Rhame F 1999 The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107:126-132
32. Coodley GO, Coodley MK 1997 A trial of testosterone therapy for HIV-associated weight loss. AIDS 11:1347-1352
33. Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M 1996 Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 75:129-138
34. Kong A, Edmonds P 2002 Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2:692-699
35. Albert SG, Mooradian AD 2004 Low-dose recombinant human growth hormone as adjuvant therapy to life style modification in the management of obesity. J Clin Endocrinol Metab 89:695-701
36. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP 2002 Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30:379-391
37. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K 2002 Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 35:1258-1262
38. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Harman M 2002 Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282-2292
39. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, Grunfeld C, Schambelan M 2002 Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87:942
40. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S 2003 Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144:5081-5088